芬吗通治疗围绝经期综合征的Meta分析

Meta-analysis of femoston in the treatment of perimenopausal syndrome

目的系统评价芬吗通治疗围绝经期综合征的效果。方法计算机检索中国知网(CNKI)、万方数据医学信息系统(WF)、维普网(VIP)、中国生物医学文献数据库(CBM)、Embase、Pubmed、Coehrane Library自建库至2020年5月8日的芬吗通治疗围绝经期综合征文献,用Cochrane系统评价文献质量、RevMan 5.3软件进行Meta分析。结果纳入文献10篇,共1472例患者(对照组741例,试验组731例),相比其他传统激素治疗围绝经期综合征,芬吗通能显著提高总有效率(P<0.01),改善血清FSH、E2、LH水平(P<0.01),Kupperman评分(P<0.01)。药物的不良反应方面,芬吗通组不良反应发生率为5.40%、传统治疗组8.34%,在阴道不规则出血、乳房胀痛方面不良反应发生风险分析差异无统计学意义(P>0.01),芬吗通组对子宫内膜厚度的不良反应小于传统治疗组。结论相比于传统激素,芬吗通治疗围绝经期综合征在提高总有效率、改善性激素水平,改善Kupperman评分,降低不良反应等方面有明显优势,没有增加阴道不规则出血、乳房胀痛方面风险,并减少对子宫内膜厚度的不良反应。

Objective To evaluate the effect of femoston on perimenopausal syndrome.Methods A computer search for relevant articles was run on China National Knowledge Infrastrucure,Wanfang Data,VIP China Science and Technology Journal database,Chinese Biomedical Literature Database,Pubmed,Embase.Retrieval time limit was from the database-established year to March 28th,2020.Two reviewers assessed the methodological quality according to Cochrane Systematic Review independently.Meta analysis was performed with RevMan 5.3 software.Results A total of 10 articles involving 1,472 patients were included(741 in the experimental group,731 in the control group).Femoston for perimenopausal syndrome could significantly improve the total effective rate(P<0.01),improve follicle-stimulating hormone level(P<0.01)、luteinizing hormone level(P<0.01)、and estriol level(P<0.01),and improve the Kupperman score(P<0.01).The incidence of adverse drug reactions was 5.40% in the experimental group and 8.34% in the control group.There was no statistical difference in risk analysis of adverse reactions in terms of irregular vaginal bleeding and breast pain(P>0.01),except the patients’endometrial thickness(P<0.05).Conclusion Femoston has an advantage in the treatment of perimenopausal syndrome over femoston alone in total effective rate,improving sex hormone levels,improving the Kupperman score,and reducing the risk of adverse drug reaction.There is no increase in the risk of adverse reactions such as irregular vaginal bleeding,breast pain and the endometrial thickness.